Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung

American Journal of Respiratory and Critical Care Medicine

Volumn 154, Issue 2, 1996, Pages 400-406

  Behr, Jürgen ^a   Vogelmeier, Claus ^b   Beinert, Thomas ^b   Meurer, Michael ^b   Krombach, Fritz ^b   König, Gerhard ^b   Fruhmann, Günter ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALLERGIC PNEUMONITIS; ARTICLE; CAUSE OF DEATH; CELL DIFFERENTIATION; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG DISEASE; LUNG FUNCTION; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCLERODERMA; STATISTICAL ANALYSIS;

EID: 0029758449     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.154.2.8756813     Document Type: Article

References (35)

1. Steen, V. D., G. R. Owens, G. J. Fino, G. P. Rodnan, and T. A. Medsger, Jr. 1985. Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum. 28:759-767.
2. Johnson, D. A., W. E. Drane, J. Curran, E. L. Cattau, Jr., C. Ciarleglio, A. Khan, J. Cotelingam, and S. B. Benjamin. 1989. Pulmonary disease in progressive systemic sclerosis. Arch. Intern. Med. 149:589-593.
3. King, T. E. 1993. Connective tissue disease. In M. I. Schwarz and T. E. King, editors. Interstitial Lung Disease. Mosby-Year Book, St. Louis. 271-308.
4. Lee, P., P. Langevitz, C. A. Alderdice, M. Aubrey, P. A. Baer, M. Baron, D. Buskila, J. P. Dutz, I. Khostanteen, S. Piper, M. Ramsden, T. O. Rosenbach, S. Sukenik, S. Wilkinson, and E. C. Keystone. 1992. Mortality in systemic sclerosis (scleroderma). Q. J. Med. 298: 139-148.
5. Weaver, A. L., M. B. Divertie, and J. L. Titus. 1968. Pulmonary scleroderma. Dis. Chest 54:490-498.
6. Edelson, J. D., R. H. Hyland, M. Ramsden, D. W. Chamberlain, P. Kortan, H. O. Meindok, M. H. Klein, A. C. Braude, P. Lee, and A. S. Rebuck. 1985. Lung inflammation in scleroderma: clinical, radiographic, physiologic and cytopathologic features. J. Rheumatol. 12:957-963.
7. Rossi, G. A., P. B. Bitterman, S. I. Rennard, V. J. Ferrans, and R. G. Crystal. 1985. Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis. Am. Rev. Respir. Dis. 131:612-617.
8. Owens, G. R., I. L. Paradis, S. Gryzan, T. F. Medsger, Jr., W. P. Follansbee, H. A. Klein, and J. H. Dauber. 1986. Role of inflammation in the lung disease of systemic sclerosis: comparison with idiopathic pulmonary fibrosis. J. Lab. Clin. Med. 107:253-260.
9. Harrison, N. K., R. J. McAnully, P. L. Haslam, C. M. Black, and G. J. Laurent. 1990. Evidence for protein oedema, neutrophil influx, and enhanced collagen production in lungs of patients with systemic sclerosis. Thorax 45:606-610.
10. Kallenberg, C. G. M., H. M. Jansen, J. D. Elema, and T. H. The. 1984. Steroid-responsive pulmonary disease in systemic sclerosis. Monitoring by bronchoalveolar lavage. Chest 86:489-492.
11. König, G., C. Luderschmidt, C. Hammer, B. C. Adelmann-Grill, O. Braun-Falco, G. Fruhmann. 1984. Lung involvement in scleroderma. Chest 85:318-324.
12. Silver, R. M., K. S. Miller, M. B. Kinsella, E. A. Smith, and S. I. Schabel. 1990. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am. J. Med. 88:470-476.
13. Hein, R., J. Behr, M. Hündgen, N. Hunzelmann, M. Meurer, O. Braun-Falco, A. Urbanski, and T. Krieg. 1992. Treatment of systemic sclerosis with gamma-interferon. Br. J. Dermatol. 126:496-501.
14. Rodnan, G. P., S. Jablonska, and T. A. Medsger. 1976. Classification and nomenclature of progressive systemic sclerosis (scleroderma). Clin. Rheum. Dis. 5:5-13.
15. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. 1980. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 23:581-590.
16. LeRoy, E. C., C. Black, R. Fleishmayer, S. Jablonska, T. Krieg, T. A. Medsger, N. Rowell, and F. Wollheim. 1988. Scleroderma (systemic sclerosis). Classification, subsets and pathogenesis. J. Rheumatol. 15: 202-205.
17. Ulmer, W. T., G. Reichel, D. Nolte, and M. S. Islam. 1983. Die Lungenfunktion - Physiologie, Pathophysiologie, Methodik. Georg Thieme Verlag, Stuttgart.
18. European Community for Coal and Steel. 1983. Standardized lung function testing. Report of the working party on standardization of lung function tests. Luxembourg, 1983. Bull. Eur. Physiopathol. Respir. 19(Suppl. 5):11-92.
19. Behr, J., B. C. Adelmann-Grill, F. Krombach, T. Beinert, M. Schwaiblmair, and G. Fruhmann. 1993. Fibroblast chemotactic response elicited by native bronchoalveolar lavage fluid from patients with fibrosing alveolitis. Thorax 48:736-742.
20. Hunninghake, G. W., J. E. Gadek, O. Kawanami, V. J. Ferrans, and R. G. Crystal. 1979. Inflammation and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage. Am. J. Pathol. 97:149-206.
21. Goldstein, R. A., P. K. Rohatgi, E. H. Bergofsky, E. R. Block, R. P. Daniele, D. R. Dantzker, G. S. Davis, G. W. Hunninghake, T. E. King, W. J. Metzger, J. A. Rankin, H. Y. Reynolds, and G. M. Turino. 1990. American Thoracic Society: Clinical role of bronchoalveolar lavage in adults with pulmonary disease. Am. Rev. Respir. Dis. 142:481-486.
22. Klech, H., and W. Pohl. 1989. Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Eur. Respir. J. 2:561-585.
23. Costable, U., J. Barth, J. Behr, R. Buhl, G. Kanzow, H. Klech, G. König, C. Kroegel, M. Magnussen, J. Müller-Quernheim, W. Petermann, W. Pohl, M. Rust, T. Schaberg, M. Schmidt, H. Steppling, H. Teschler, T. O. F. Wagner, and H. Worth. 1993. Deutsche Gesellschaft für Pneumologie. Empfehlungen zur diagnostischen bronchoalveolären Lavage. Pneumologie 47:607-619.
24. Goldstein, R. H., and A. Fine. 1986. Fibrotic reactions in the lung: the activation of the lung fibroblast. Exp. Lung Res. 11:245-261.
25. Libby, P., G. B. Friedman, and R. N. Salomon. 1989. Cytokines as modulators of cell proliferation in fibrotic disease. Am. Rev. Respir. Dis. 140:1114-1117.
26. Elias, J. A., B. Freundlich, J. A. Kern, and J. Rosenbloom. 1990. Cytokine networks in the regulation of inflammation and fibrosis in the lung. Chest 97:1439-1445.
27. Kelley, J. 1990. Cytokines of the lung. Am. Rev. Respir. Dis. 141:765-788.
28. Albini, A., B. C. Adelmann-Grill, and P. K. Müller. 1985. Fibroblast chemotaxis. Collagen Rel. Res. 5:283-296.
29. Spencer, H. 1977. Lung changes in progressive systemic sclerosis. In H. Spencer, editor. Pathology of the Lung. Pergamon Press, Oxford, England. 741-746.
30. D'Angelo, W. A., J. F. Fires, A. T. Masi, and L. E. Shulman. 1969. Pathologic observations in systemic sclerosis. Am. J. Med. 46:428-440.
31. Steen, V. D., G. R. Owens, C. Redmond, G. P. Rodnan, and T. A. Medsger, Jr. 1985. The effect of d-penicillamine on pulmonary findings in systemic sclerosis. Arthritis Rheum. 28:882-888.
32. deClerck, L. S., J. Dequeker, L. Francx, and M. Demedts. 1987. D-penicillamine therapy and interstitial lung disease in scleroderma. A long-term followup study. Arthritis Rheum. 30:643-650.
33. Akesson, A., A. Scheja, A. Lundin, and F. A. Wollheim. 1994. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum. 37:729-735.
34. Silver, R. M., J. H. Warrick, M. B. Kinsella, L. S. Staudt, M. H. Baumann, and C. Strange. 1993. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J. Rheumatol. 20:834-844.
35. Steen, V. D., J. K. Lanz, C. Conte, G. R. Owens, and T. A. Medsger, Jr. 1994. Therapy for severe interstitial lung disease in systemic sclerosis. Arthritis Rheum. 37:1290-1296.